组蛋白去乙酰化酶抑制剂在心脏重构中的机制和应用

张欣茹; 孔春燕; 唐其柱

doi:10.14188/j.1671-8852.2024.0144

您当前的位置：

首页 >

文章列表页 >

组蛋白去乙酰化酶抑制剂在心脏重构中的机制和应用

综述与Meta分析 | 更新时间：2026-11-05

- 组蛋白去乙酰化酶抑制剂在心脏重构中的机制和应用
- Mechanism and application of histone deacetylase inhibitors in cardiac remodeling
- 武汉大学学报（医学版） 2025年46卷第11期页码：1500-1505
- 作者机构：
  
  武汉大学人民医院心血管内科/代谢与相关慢病湖北省重点实验室湖北武汉 430060
- 作者简介：
  
  张欣茹，女，2001—，医学硕士生，主要从事心血管疾病的研究，E⁃mail: zhangxinru@whu.edu.cn
  唐其柱，男，1963—，医学博士，主任医师，教授，博士生导师，主要从事心血管及慢性疾病的研究，E⁃mail: qztang@whu.edu.cn
- 基金信息：
  
  国家自然科学基金区域创新发展联合基金项目(U22A20269)
- DOI：10.14188/j.1671-8852.2024.0144
  中图分类号： R54
- 收稿：2024-03-03，
  
  纸质出版：2025-11-25
- 稿件说明：
移动端阅览
张欣茹,孔春燕,唐其柱.组蛋白去乙酰化酶抑制剂在心脏重构中的机制和应用[J].武汉大学学报（医学版）,2025,46(11):1500-1505.

ZHANG Xinru,KONG Chunyan,TANG Qizhu.Mechanism and application of histone deacetylase inhibitors in cardiac remodeling[J].Medical Journal of Wuhan University,2025,46(11):1500-1505.
张欣茹,孔春燕,唐其柱.组蛋白去乙酰化酶抑制剂在心脏重构中的机制和应用[J].武汉大学学报（医学版）,2025,46(11):1500-1505. DOI： 10.14188/j.1671-8852.2024.0144.

ZHANG Xinru,KONG Chunyan,TANG Qizhu.Mechanism and application of histone deacetylase inhibitors in cardiac remodeling[J].Medical Journal of Wuhan University,2025,46(11):1500-1505. DOI： 10.14188/j.1671-8852.2024.0144.

摘要

组蛋白的乙酰化/去乙酰化参与调控多种信号通路，在影响基因表达和应激导致的心脏病理性重构中起着关键作用。应用组蛋白去乙酰化酶抑制剂能显著改善心脏重构，逆转病态纤维化及心肌细胞肥大。该文将就组蛋白去乙酰化酶抑制剂对心脏的保护作用进行综述，并简要介绍几种在改善心脏重构上具有应用前景的组蛋白去乙酰化酶抑制剂。

Abstract

Acetylation/deacetylation of histones is involved in the regulation of various signaling pathways and plays a key role in modulating gene expression and stress⁃induced pathological remodeling of the heart. Histone deacetylase inhibitors significantly ameliorate cardiac remodeling

reverse pathological fibrosis

and attenuate cardiomyocyte hypertrophy. This review summarizes the cardioprotective effects of HDAC inhibitors and briefly introduces several compounds with therapeutic prospects for improving cardiac remodeling.

关键词

Keywords

references

ZHANG L , CHEN B , ZHAO Y , et al . Inhibition of histone deacetylase induced myocardial repair is mediated by c⁃kit in infarcted hearts [J ] . J Biol Chem , 2012 , 287 : 39338 ⁃ 39348 .

ZHANG L , QIN X , ZHAO Y , et al . Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis [J ] . J Pharmacol Exp Ther , 2012 , 341 : 285 ⁃ 293 .

MCKINSEY T A , KASS D A . Small⁃molecule therapies for cardiac hypertrophy: Moving beneath the cell surface [J ] . Nat Rev Drug Discov , 2007 , 6 : 617 ⁃ 635 .

ZHAO L , CHENG G , CHOKSI K , et al . Transplantation of human umbilical cord blood⁃derived cellular fraction of human umbilical cord blood⁃derived cellular fraction improves left ventricular function and remodeling after myocardial ischemia/reperfusion [J ] . Circ Res , 2019 , 125 ( 8 ): 759 ⁃ 772 .

GROBE J L , DER SARKISSIAN S , STEWART J M , et al . ACE2 overexpression inhibits hypoxia induced collagen production by cardiac fibroblasts [J ] . Clin Sci (Lond) , 2007 , 113 ( 8 ): 357 ⁃ 364 .

WANG Y , MIAO X , LIU Y , et al . Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases [J ] . Oxid Med Cell Longev , 2014 , 2014 ( 1 ): 641979 .

YANG M , ZHANG Y , REN J . Acetylation in cardiovascular diseases: Molecular mechanisms and clinical implications [J ] . Biochim Biophys Acta Mol Basis Dis , 2020 , 1866 ( 10 ): 165836 .

FUNAMOTO M , IMANISHI M , TSUCHIYA K , et al . Roles of histone acetylation sites in cardiac hypertrophy and heart failure [J ] . Front Cardiovasc Med , 2023 , 10 : 1133611 .

MATSUSHIMA S , SADOSHIMA J . The role of sirtuins in cardiac disease [J ] . Am J Physiol Heart Circ Physiol , 2015 , 309 ( 9 ): H1375 ⁃H1389.

HOLBERT M A , MARMORSTEIN R . Structure and activity of enzymes that remove histone modifications [J ] . Current Opinion Structural Biology , 2005 , 15 ( 6 ): 673 ⁃ 680 .

GREGORETTI I V , LEE Y M , GOODSON H V . Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis [J ] . J Mol Biol , 2004 , 338 ( 1 ): 17 ⁃ 31 .

EOM G H , KOOK H . Posttranslational modifications of histone deacetylases: Implications for cardiovascular diseases [J ] . Pharmacol Ther , 2014 , 143 ( 2 ): 168 ⁃ 180 .

HOLBERT M A , MARMORSTEIN R . Structure and activity of enzymes that remove histone modifications [J ] . Curr Opin Struct Biol , 2005 , 15 ( 6 ): 673 ⁃ 680 .

KELLY R D , COWLEY S M . The physiological roles of histone deacetylase (HDAC)1 and 2: Complex co⁃stars with multiple leading parts [J ] . Biochem Soc Trans , 2013 , 41 ( 3 ): 741 ⁃ 749 .

MCKINSEY T A . The biology and therapeutic implications of HDACs in the heart [J ] . Handb Exp Pharmacol , 2011 , 206 : 57 ⁃ 78 .

BUSH E W , MCKINSEY T A . Targeting histone deacetylases for heart failure [J ] . Expert Opin Ther Targets , 2009 , 13 ( 7 ): 767 ⁃ 784 .

BUSH E W , MCKINSEY T A . Protein acetylation in the cardiorenal axis: The promise of histone deacetylase inhibitors [J ] . Circ Res , 2010 , 106 ( 2 ): 272 ⁃ 284 .

ZHAO T , KEE H J , BAI L , et al . Selective HDAC8 inhibition attenuates isoproterenol induced cardiac hypertrophy and fibrosis via p38 MAPK pathway [J ] . Front Pharmacol , 2021 , 12 : 677757 .

HEWITSON R , DARGAN J , COLLIS D , et al . Heart failure: The pivotal role of histone deacetylases [J ] . Int J Biochem Cell Biol , 2013 , 45 ( 2 ): 448 ⁃ 453 .

LIN Y H , MAJOR J L , LIEBNER T , et al . HDAC6 modulates myofibril stiffness and diastolic function of the heart [J ] . J Clin Invest , 2022 , 132 ( 10 ): e148333 .

DEMOS DAVIES K M , FERGUSON B S , CAVASIN M A , et al . HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin⁃Ⅱ signaling [J ] . Am J Physiol Heart Circ Physiol , 2014 , 307 ( 2 ): H252 ⁃H258.

SANBE A , INOMATA Y , MATSUSHITA N , et al . Modification of cardiac disease by transgenically altered histone deacetylase 6 [J ] . Biochem Biophys Res Commun , 2022 , 631 : 48 ⁃ 54 .

GUO L , YIN A , ZHANG Q , et al . Angiotensin(1⁃7) attenuates angiotensin Ⅱ induced cardiac hypertrophy via a Sirt3⁃dependent mechanism [J ] . Am J Physiol Heart Circ Physiol , 2017 , 312 ( 5 ): H980 ⁃H991.

YU L , GONG B , DUAN W , et al . Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: Role of AMPK⁃PGC⁃1α⁃SIRT3 signaling [J ] . Sci Rep , 2017 , 7 : 41337 .

LI Z , ZHANG X , GUO Z , et al . SIRT6 suppresses NFATc4 expression and activation in cardiomyocyte hypertrophy [J ] . Front Pharmacol , 2019 , 9 : 1519 .

YOON S , EOM G H . HDAC and HDAC inhibitor: From cancer to cardiovascular diseases [J ] . Chonnam Med J , 2016 , 52 ( 1 ): 1 ⁃ 11 .

LIU L , ZHAO W , LIU J , et al . Epigallocatechin⁃3 gallate prevents pressure overload induced heart failure by up⁃regulating SERCA2a via histone acetylation modification in mice [J ] . PLoS One , 2018 , 13 ( 10 ): e0205123 .

BAGCHI R A , WEEKS K L . Histone deacetylases in cardiovascular and metabolic diseases [J ] . J Mol Cell Cardiol , 2019 , 130 : 151 ⁃ 159 .

CHEN Y , DU J , ZHAO Y T , et al . Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice [J ] . Cardiovasc Diabetol , 2015 , 14 : 99 .

JEONG M Y , LIN Y H , WENNERSTEN S A , et al . Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism [J ] . Sci Transl Med , 2018 , 10 ( 427 ): eaao0144 .

WALLNER M , EATON D M , BERRETTA R M , et al . HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction [J ] . Sci Transl Med , 2020 , 12 ( 525 ): eaay7205 .

NURAL⁃GUVENER H F , ZAKHAROVA L , NIMLOS J , et al . HDAC class Ⅰ inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90 + cardiac myofibroblast activation [J ] . Fibrogenesis Tissue Repair , 2014 , 7 : 10 .

CAO D J , WANG Z V , BATTIPROLU P K , et al . Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy [J ] . P Proc Natl Acad Sci U S A , 2011 , 108 ( 10 ): 4123 ⁃ 4128 .

MCKINSEY T A . Therapeutic potential for HDAC inhibitors in the heart [J ] . Annu Rev Pharmacol Toxicol , 2012 , 52 : 303 ⁃ 319 .

KEE H J , KOOK H . Kruppel⁃like factor 4 mediates histone deacetylase inhibitor induced prevention of cardiac hypertrophy [J ] . J Mol Cell Cardiol , 2009 , 47 ( 6 ): 770 ⁃ 780 .

STRATTON M S , LIN C Y , ANAND P , et al . Signal dependent recruitment of BRD4 to cardiomyocyte super⁃enhancers is suppressed by a microRNA [J ] . Cell Rep , 2016 , 16 ( 5 ): 1366 ⁃ 1378 .

FERGUSON B S , HARRISON B C , JEONG M Y , et al . Signal dependent repression of DUSP5 by class Ⅰ HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy [J ] . Proc Natl Acad Sci U S A , 2013 , 110 ( 24 ): 9806 ⁃ 9811 .

KUMARSWAMY R , VOLKMANN I , JAZBUTYTE V , et al . Transforming growth factor⁃β induced endothelial to mesenchymal transition is partly mediated by microRNA⁃21 [J ] . Arterioscler Thromb Vasc Biol , 2012 , 32 ( 2 ): 361 ⁃ 369 .

WIDYANTORO B , EMOTO N , NAKAYAMA K , et al . Endothelial cell derived endothelin⁃1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial to mesenchymal transition [J ] . Circulation , 2010 , 121 ( 22 ): 2407 ⁃ 2418 .

MAK T W , HAUCK L , GROTHE D , et al . p53 regulates the cardiac transcriptome [J ] . Proc Natl Acad Sci U S A , 2017 , 114 ( 9 ): 2331 ⁃ 2336 .

STANLEY⁃HASNAIN S , HAUCK L , GROTHE D , et al . P53 and Mdm2 act synergistically to maintain cardiac homeostasis and mediate cardiomyocyte cell cycle arrest through a network of microRNAs [J ] . Cell Cycle , 2017 , 16 ( 17 ): 1585 ⁃ 1600 .

MOORE J B 4th , ZHAO J , KEITH M C , et al . The epigenetic regulator HDAC1 modulates transcription of a core cardiogenic program in human cardiac mesenchymal stromal cells through a p53 dependent mechanism [J ] . Stem Cells , 2016 , 34 ( 12 ): 2916 ⁃ 2929 .

ZHAO Y , LU S L , WU L P , et al . Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1) [J ] . Mol Cell Biol , 2006 , 26 ( 7 ): 2782 ⁃ 2790 .

BARBOSA D M , FAHLBUSCH P , HERZFELD DE WIZA D , et al . Rhein, a novel Histone Deacetylase (HDAC) inhibitor with antifbrotic potency in human myocardial fbrosis [J ] . Sci Rep , 2020 , 10 ( 1 ): 4888 .

ZHANG L , DENG M , LU A , et al . Sodium butyrate attenuates angiotensin Ⅱ induced cardiac hypertrophy by inhibiting COX2/PGE2 pathway via a HDAC5/HDAC6 dependent mechanism [J ] . J Cell Mol Med , 2019 , 23 ( 12 ): 8139 ⁃ 8150 .

HAN X , PENG C , HUANG L , et al . EGCG prevents pressure overload induced myocardial remodeling by downregulating overexpression of HDAC5 in mice [J ] . Int J Mol Med , 2021 , 49 ( 1 ): 11 .

PAN B , QUAN J , LIU L , et al . Epigallocatechin gallate reverses cTnI low expression induced age related heart diastolic dysfunction through histone acetylation modification [J ] . J Cell Mol Med , 2017 , 21 ( 10 ): 2481 ⁃ 2490 .

MOORE J B 4th , TANG X L , ZHAO J , et al . Epigenetically modified cardiac mesenchymal stromal cells limit myocardial fibrosis and promote functional recovery in a model of chronic ischemic cardiomyopathy [J ] . Basic Res Cardiol , 2018 , 114 ( 1 ): 3 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

苦参酮对心脏缺血再灌注诱导心肌重构的影响和机制

探索CASIA2与Pentacam在白内障术前评估中的差异：基于前房容积、角膜厚度及瞳孔直径的测量对比

ADAMTS4在急性肺损伤/急性呼吸窘迫综合征中的研究进展

重复经颅磁刺激改善阿尔茨海默病模型小鼠的突触超微结构

预防性镇痛联合阶梯式干预对学龄期急性阑尾炎患儿疼痛控制的影响